G-749FLT3 inhibitor CAS# 1457983-28-6 |
- Cabozantinib (XL184, BMS-907351)
Catalog No.:BCC1264
CAS No.:849217-68-1
- Amuvatinib (MP-470, HPK 56)
Catalog No.:BCC2258
CAS No.:850879-09-3
- TG101209
Catalog No.:BCC2198
CAS No.:936091-14-4
- Ponatinib (AP24534)
Catalog No.:BCC2522
CAS No.:943319-70-8
- Quizartinib (AC220)
Catalog No.:BCC2548
CAS No.:950769-58-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1457983-28-6 | SDF | Download SDF |
| PubChem ID | 78357765 | Appearance | Powder |
| Formula | C25H25BrN6O2 | M.Wt | 521.41 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 25 mg/mL (47.95 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-(4-phenoxyanilino)-6H-pyrido[4,3-d]pyrimidin-5-one | ||
| SMILES | CN1CCC(CC1)NC2=NC3=C(C(=O)NC=C3Br)C(=N2)NC4=CC=C(C=C4)OC5=CC=CC=C5 | ||
| Standard InChIKey | SXWMIXPJPNCXQQ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C25H25BrN6O2/c1-32-13-11-17(12-14-32)29-25-30-22-20(26)15-27-24(33)21(22)23(31-25)28-16-7-9-19(10-8-16)34-18-5-3-2-4-6-18/h2-10,15,17H,11-14H2,1H3,(H,27,33)(H2,28,29,30,31) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | G-749 is a novel FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants with IC50s of 0.4/0.6/3.5/7.5 nM for Wt Flt3/D835Y/MV4-11/Molm-14 respectively.
IC50 value: 0.4/0.6/3.5/7.5 nM(Wt Flt3/D835Y/MV4-11/Molm-14) [1]
Target: Flt3 inhibitor
G-749 showed potent and sustained inhibition of the FLT3 wild type and mutants including FLT3-ITD, FLT3-D835Y, FLT3-ITD/N676D, and FLT3-ITD/F691L in cellular assays. G-749 retained its inhibitory potency in various drug-resistance milieus such as patient plasma, FLT3 ligand surge, and stromal protection. Furthermore, it displayed potent antileukemic activity in bone marrow blasts from AML patients regardless of FLT3 mutation status, including those with little or only minor responses to AC220 or PKC412. Oral administration of G-749 yielded complete tumor regression and increased life span in animal models. References: | |||||
G-749 Dilution Calculator
G-749 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9179 mL | 9.5894 mL | 19.1788 mL | 38.3575 mL | 47.9469 mL |
| 5 mM | 0.3836 mL | 1.9179 mL | 3.8358 mL | 7.6715 mL | 9.5894 mL |
| 10 mM | 0.1918 mL | 0.9589 mL | 1.9179 mL | 3.8358 mL | 4.7947 mL |
| 50 mM | 0.0384 mL | 0.1918 mL | 0.3836 mL | 0.7672 mL | 0.9589 mL |
| 100 mM | 0.0192 mL | 0.0959 mL | 0.1918 mL | 0.3836 mL | 0.4795 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
G-749 is a selective inhibitor of Fms-like tyrosine receptor kinase-3 (FLT3) with IC50 value of 0.4 nM for wild-type FLT31.
G-749 is a synthesized and ATP-competitive inhibitor of wild-type FLT3 with high potency. It inhibited the autophosphorylation of FLT3 with IC50 value of ≤ 8 nM in RS4-11 leukemia cells. It also has inhibitory activity against various FLT3 mutants. In BaF3 cell lines that stably express FLT3-ITD/N676D, -ITD/F691L, -D835Y or -D835Y/N676D, G-749 showed strong potency against autophosphorylation of all tested FLT3 mutants with IC50 of < 10 nM. In MV4-11 and Molm-14 cell lines addicted to FLT3-ITD, G-749 significantly suppressed cell proliferation as well as increased active caspase 3/7 level and cleaved PARP in a dose-dependent manner. Besides that, G-749 showed high potency against p-FLT3, p-ERK1/2 and p-AKT even in high FLT3 ligand milieu1.
References:
1. Lee H K, Kim H W, Lee I Y, et al. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood, 2014, 123(14): 2209-2219.
- 4,6-Dichloro-2-(propylthio)pyrimidin-5-amine
Catalog No.:BCC8666
CAS No.:145783-15-9
- 4,6-Dichloro-5-nitro-2-propylthiopyrimidine
Catalog No.:BCC8667
CAS No.:145783-14-8
- AR-C 66096 tetrasodium salt
Catalog No.:BCC6004
CAS No.:145782-74-7
- 3-Allylrhodanine
Catalog No.:BCC8604
CAS No.:1457-47-2
- HG-9-91-01
Catalog No.:BCC4071
CAS No.:1456858-58-4
- SH-4-54
Catalog No.:BCC5483
CAS No.:1456632-40-8
- 2'-O-Benzoylpaeoniflorin
Catalog No.:BCN7803
CAS No.:1456598-64-3
- NNC 711
Catalog No.:BCC7176
CAS No.:145645-62-1
- Cyclocommunol
Catalog No.:BCN3375
CAS No.:145643-96-5
- Sophocarpine
Catalog No.:BCN5971
CAS No.:145572-44-7
- Eucamalol
Catalog No.:BCN1648
CAS No.:145544-91-8
- Mitiglinide Calcium
Catalog No.:BCC5000
CAS No.:145525-41-3
- Margatoxin
Catalog No.:BCC7709
CAS No.:145808-47-5
- Tiagabine hydrochloride
Catalog No.:BCC5217
CAS No.:145821-59-6
- D-myo-Inositol-1,3,4,5-tetrakisphosphate, octapotassium salt
Catalog No.:BCC7058
CAS No.:145843-69-2
- Brachynoside
Catalog No.:BCN3749
CAS No.:145898-87-9
- CGP 52411
Catalog No.:BCC7667
CAS No.:145915-58-8
- CGP 53353
Catalog No.:BCC7363
CAS No.:145915-60-2
- 7,8,9,9-Tetradehydroisolariciresinol
Catalog No.:BCN1649
CAS No.:145918-59-8
- 3-Amino-3-phenyl-1-propanol
Catalog No.:BCC8608
CAS No.:14593-04-5
- 2-(Methylamino)ethylphosphonic acid
Catalog No.:BCN1763
CAS No.:14596-55-5
- 2-Dimethylaminoethylphosphonic acid
Catalog No.:BCN1764
CAS No.:14596-56-6
- N,N,N-Trimethyl-2-aminoethylphosphonate
Catalog No.:BCN1560
CAS No.:14596-57-7
- Laccaic acid E
Catalog No.:BCN1807
CAS No.:14597-16-1
G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.[Pubmed:24532805]
Blood. 2014 Apr 3;123(14):2209-19.
Aberrant activations of Fms-like tyrosine receptor kinase (FLT) 3 are implicated in the pathogenesis of 20% to 30% of patients with acute myeloid leukemia (AML). G-749 is a novel FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants including FLT3-ITD, FLT3-D835Y, FLT3-ITD/N676D, and FLT3-ITD/F691L in cellular assays. G-749 retained its inhibitory potency in various drug-resistance milieus such as patient plasma, FLT3 ligand surge, and stromal protection. Furthermore, it displayed potent antileukemic activity in bone marrow blasts from AML patients regardless of FLT3 mutation status, including those with little or only minor responses to AC220 or PKC412. Oral administration of G-749 yielded complete tumor regression and increased life span in animal models. Thus, G-749 appears to be a promising next-generation drug candidate for the treatment of relapsed and refractory AML patients with various FLT3-ITD/FLT3-TKD mutants and further shows the ability to overcome drug resistance.
